Inhaltsbereich
| 66 Einträge | 1, 2, 3, 4 › » |
Seite 1 / 4
 Druckansicht
|
| Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. |
| Goodson WH, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z |
| Carcinogenesis. 2015 Jun 24. pii: bgv039. doi: 10.1093/carcin/bgv039. pmc: PMC4480130 |
| PMID: 26106142 |
| Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. |
| Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Aug 10. pii: JCO.2015.61.2887. doi: 10.1200/JCO.2015.61.2887 |
| PMID: 26261259 |
| Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. |
| Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, Taphoorn M, Soffietti R, Weller M |
| The Lancet. Oncology. 2015 Jul 7. pii: S1470-2045(15)00076-5. doi: 10.1016/S1470-2045(15)00076-5 |
| PMID: 26149884 |
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. |
| Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S |
| The Lancet. Oncology. 2014 Jul 31. pii: S1470-2045(14)70330-4. doi: 10.1016/S1470-2045(14)70330-4 |
| PMID: 25088940 |
| Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. |
| Cserni G, Vörös A, Liepniece-Karele I, Bianchi S, Vezzosi V, Grabau D, Sapino A, Castellano I, Regitnig P, Foschini MP, Zolota V, Varga Z, Figueiredo P, Decker T, Focke C, Kulka J, Kaya H, Reiner-Concin A, Amendoeira I, Callagy G, Caffrey E, Wesseling J, Wells C |
| Breast (Edinburgh, Scotland). 2014 Mar 7. pii: S0960-9776(14)00031-9. doi: 10.1016/j.breast.2014.02.003 |
| PMID: 24613255 |
| Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma. |
| Schmidinger M, Szczylik C, Sternberg CN, Kania M, Kelly CS, Decker R, Hamid O, Faelker T, Escudier B |
| American journal of clinical oncology. 2012 Sep 19. doi: 10.1097/COC.0b013e31821cfc41 |
| PMID: 21654314 |
| Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. |
| Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, Wu X, Pan S, Mickel L, Schuster C, Stary G, Jalili A, David OJ, Emotte C, Antunes AM, Rose K, Decker J, Carlson I, Gardner H, Stuetz A, Bertolino AP, Stingl G, De Rie MA |
| The Journal of investigative dermatology. 2011 Mar 24. pii: jid201148. doi: 10.1038/jid.2011.48 |
| PMID: 21430703 |
| Usability and safety of ventricular assist devices: human factors and design aspects. |
| Geidl L, Zrunek P, Deckert Z, Zimpfer D, Sandner S, Wieselthaler G, Schima H |
| Artificial organs. 2009 Sep 24. pii: AOR844. doi: 10.1111/j.1525-1594.2009.00844.x |
| PMID: 19775260 |
| Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. |
| Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, Chang-Rodriguez S, Lingnau K, Weisz E, Putz EM, Pickl WF, Felzmann T, Müller M, Decker T, Sexl V, Stoiber D |
| Cancer research. 2009 Jan 1. pii: 69/1/203. doi: 10.1158/0008-5472.CAN-08-1705 |
| PMID: 19118004 |
| Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis. |
| Hainzl E, Stockinger S, Rauch I, Heider S, Berry D, Lassnig C, Schwab C, Rosebrock F, Milinovich G, Schlederer M, Wagner M, Schleper C, Loy A, Urich T, Kenner L, Han X, Decker T, Strobl B, Müller M |
| Journal of immunology (Baltimore, Md. : 1950). 2015 Oct 2. pii: jimmunol.1402565. doi: 10.4049/jimmunol.1402565. pmc: PMC4635564 |
| PMID: 26432894 |
| Consistency in recognizing microinvasion in breast carcinomas is improved by immunohistochemistry for myoepithelial markers. |
| Cserni G, Wells CA, Kaya H, Regitnig P, Sapino A, Floris G, Decker T, Foschini MP, van Diest PJ, Grabau D, Reiner A, DeGaetano J, Chmielik E, Cordoba A, Andreu X, Zolota V, Charafe-Jauffret E, Ryska A, Varga Z, Weingertner N, Bellocq JP, Liepniece-Karele I, Callagy G, Kulka J, Bürger H, Figueiredo P, Wesseling J, Amendoeira I, Faverly D, Quinn CM, Bianchi S |
| Virchows Archiv : an international journal of pathology. 2016 Jan 27. doi: 10.1007/s00428-016-1909-x. pii: 10.1007/s00428-016-1909-x |
| PMID: 26818833 |
| CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). |
| Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V |
| Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016 May 27. pii: mdw222. doi: 10.1093/annonc/mdw222 |
| PMID: 27234640 |
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306. |
| Stintzing S, Neumann J, Jung A, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jaeger E, Heintges T, Stoll C, Modest DP, Kirchner T, Scheithauer W, Heinemann V |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jun 15. pii: 10.1200/jco.2011.29.15_suppl.3575 |
| PMID: 28020264 |
| Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306). |
| Modest DP, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Kirchner T, Jung A, Stauch M, von Einem JC, Moehler M, Held S, Heinemann V |
| International journal of cancer. 2016 Dec 29. doi: 10.1002/ijc.30592 |
| PMID: 28032641 |
| Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). |
| Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller J, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Schaefer B, Modest DP, Jung A, Stintzing S |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 31. doi: 10.1200/jco.2013.31.18_suppl.lba3506 |
| PMID: 28136074 |
| 508PD2ND-LINE THERAPIES AFTER 1ST-LINE THERAPY WITH FOLFIRI IN COMBINATION WITH CETUXIMAB OR BEVACIZUMAB IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)-ANALYSIS OF THE AIO KRK 0306 (FIRE 3)- TRIAL. |
| Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen C, Jung A, Kirchner T, Heinemann V |
| Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Feb 7. pii: 2241266. doi: 10.1093/annonc/mdu333.11 |
| PMID: 28172083 |
| The Tumor Suppressor Hace1 Is a Critical Regulator of TNFR1-Mediated Cell Fate. |
| Tortola L, Nitsch R, Bertrand MJM, Kogler M, Redouane Y, Kozieradzki I, Uribesalgo I, Fennell LM, Daugaard M, Klug H, Wirnsberger G, Wimmer R, Perlot T, Sarao R, Rao S, Hanada T, Takahashi N, Kernbauer E, Demiröz D, Lang M, Superti-Furga G, Decker T, Pichler A, Ikeda F, Kroemer G, Vandenabeele P, Sorensen PH, Penninger JM |
| Cell reports. 2016 May 5. pii: S2211-1247(16)30445-4. doi: 10.1016/j.celrep.2016.04.032. pmc: PMC4893156 |
| PMID: 27160902 |
| Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). |
| Modest DP, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Westphalen CB, Holch JW, von Einem JC, Held S, Heinemann V |
| European journal of cancer (Oxford, England : 1990). 2017 Aug 23. pii: S0959-8049(17)31150-4. doi: 10.1016/j.ejca.2017.07.030 |
| PMID: 28843184 |
| Fluorinated phenmetrazine "legal highs" act as substrates for high-affinity monoamine transporters of the SLC6 family. |
| Mayer FP, Burchardt NV, Decker AM, Partilla JS, Li Y, McLaughlin G, Kavanagh PV, Sandtner W, Blough BE, Brandt SD, Baumann MH, Sitte HH |
| Neuropharmacology. 2017 Oct 6. pii: S0028-3908(17)30473-2. doi: 10.1016/j.neuropharm.2017.10.006 |
| PMID: 28988906 |
| Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial. |
| Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V |
| International journal of cancer. 2017 Oct 19. doi: 10.1002/ijc.31114 |
| PMID: 29047142 |
| 66 Einträge | 1, 2, 3, 4 › » |
Seite 1 / 4
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
